PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930145
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930145
GLP-2 Analogs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of GLP-2 analogs Market
The global GLP-2 analogs market is experiencing steady growth due to the increasing prevalence of gastrointestinal disorders, particularly short bowel syndrome (SBS). GLP-2 analogs (glucagon-like peptide-2 analogs) are therapeutic agents that mimic the action of the naturally occurring GLP-2 hormone, which plays a crucial role in intestinal growth, nutrient absorption, and gut integrity. These drugs are primarily used in patients with SBS who depend on intravenous nutrition and fluids due to intestinal failure.
According to the report, the global GLP-2 analogs market was valued at USD 1.20 billion in 2025. The market is projected to grow to USD 1.83 billion in 2026 and further reach USD 2.65 billion by 2034, registering a CAGR of 6.08% during the forecast period (2026-2034). North America dominated the global market in 2025 with a 77.11% share, supported by advanced healthcare infrastructure, high adoption of innovative therapies, and strong clinical research activity.
Market Drivers
The primary driver of the GLP-2 analogs market is the rising global prevalence of short bowel syndrome. SBS commonly occurs due to extensive gastrointestinal surgeries, congenital defects, Crohn's disease, or other conditions resulting in reduced intestinal length and impaired nutrient absorption. Improved diagnostic capabilities and higher survival rates among intestinal failure patients have expanded the treatable patient population, directly increasing demand for GLP-2 analog therapies.
In addition, increasing clinical awareness of intestinal rehabilitation therapies and the proven ability of GLP-2 analogs to reduce dependence on total parenteral nutrition (TPN) are further fueling market growth. These therapies significantly improve patients' quality of life by enhancing intestinal absorption and decreasing long-term complications associated with TPN.
Market Restraints
Despite their clinical benefits, high treatment costs remain a major restraint for market growth. GLP-2 analog therapies involve complex manufacturing processes and substantial R&D investments. Moreover, these treatments often require daily or long-term administration, leading to a high annual financial burden on patients and healthcare systems. Cost constraints, especially in developing and price-sensitive regions, limit wider adoption and slow overall market expansion.
Market Opportunities
The market presents strong growth opportunities with the development of long-acting GLP-2 analogs. Pharmaceutical companies are increasingly focusing on weekly-dose formulations that improve patient compliance and reduce the inconvenience associated with daily injections. Pipeline candidates such as glepaglutide and apraglutide are designed to provide sustained therapeutic effects with reduced dosing frequency, which is expected to positively influence market growth.
Additionally, innovations in formulation stability and drug delivery technologies are expected to enhance therapeutic efficacy and expand future clinical applications of GLP-2 analogs.
Market Challenges
The GLP-2 analogs market faces challenges related to stringent regulatory requirements for biologic drugs. Regulatory authorities require extensive clinical trials to ensure long-term safety and efficacy, particularly due to concerns related to gastrointestinal adverse effects and other potential risks. These regulatory hurdles increase development costs, extend approval timelines, and may delay the commercialization of new pipeline products, thereby restraining market growth.
Market Trends
A major trend shaping the market is the shift from total parenteral nutrition to GLP-2-based drug therapies for managing short bowel syndrome. GLP-2 analogs offer a more targeted and physiological treatment approach by improving intestinal function and reducing reliance on invasive nutritional support.
Another important trend is the expansion of clinical indications beyond SBS. Ongoing research is evaluating the potential use of GLP-2 analogs in Crohn's disease, ulcerative colitis, chemotherapy-induced enteropathy, and steroid-refractory gastrointestinal graft-versus-host disease, which may broaden future market opportunities.
Segmentation Analysis
By drug type, the market is segmented into teduglutide and others. The teduglutide segment dominates the market due to its proven safety profile, established clinical efficacy, and regulatory approvals for SBS treatment. Other drugs, including long-acting investigational analogs, are expected to grow steadily during the forecast period.
Based on route of administration, the market is divided into parenteral and oral. The parenteral segment holds the largest share, as most approved GLP-2 analogs are injectable therapies used in intestinal failure patients. However, the oral segment is gaining traction due to higher patient compliance and advancements in oral peptide delivery systems.
By distribution channel, online and retail pharmacies account for a significant share due to improved accessibility and convenience, while hospital pharmacies continue to hold an important position owing to high inpatient treatment volumes.
Regional Outlook
North America led the global GLP-2 analogs market in 2025, with a market value of USD 1.23 billion, which increased to USD 1.43 billion in 2026. High adoption of advanced therapies, strong reimbursement frameworks, and robust R&D activities drive regional dominance. Europe holds a significant market share due to rising SBS prevalence and high healthcare spending. The Asia Pacific region is expected to witness substantial growth during the forecast period, supported by expanding clinical research and government initiatives for rare diseases. Latin America and the Middle East & Africa are anticipated to grow steadily, driven by rising awareness and improving access to advanced treatments.
Competitive Landscape
The GLP-2 analogs market is moderately concentrated, with key players such as Takeda Pharmaceutical Company Limited, Zealand Pharma, and Hanmi Pharm Co., Ltd. holding significant market shares. Takeda's strong position is supported by its approved GLP-2 analog teduglutide, extensive global presence, and high R&D investment. Other companies, including Ironwood, Entera Bio, OxThera, and Merck KGaA, are actively advancing pipeline products and expanding clinical research to strengthen their competitive positioning in the global market.
Conclusion
The GLP-2 analogs market is positioned for sustained growth, driven by the rising prevalence of short bowel syndrome (SBS) and increasing clinical adoption of targeted intestinal rehabilitation therapies. Valued at USD 1.20 billion in 2025, the market is projected to expand to USD 1.83 billion in 2026 and further reach USD 2.65 billion by 2034, growing at a CAGR of 6.08% during 2026-2034. The strong dominance of North America, supported by advanced healthcare infrastructure, high treatment adoption, and robust R&D activity, continues to shape the global market landscape.
While high treatment costs and stringent regulatory requirements remain key challenges, ongoing innovation-particularly the development of long-acting GLP-2 analogs and expansion into new clinical indications-offers meaningful growth potential. Established therapies such as teduglutide continue to anchor market demand, while pipeline candidates are expected to enhance patient compliance and broaden therapeutic options. Overall, continued clinical research, regulatory progress, and expanding awareness of SBS management are expected to support steady market expansion through 2034.
Segmentation By Drug
- Teduglutide
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Online & Retail Pharmacies
By Geography
- North America (By Drug, Route of Administration, Distribution Channel, and Country/ Sub-region)
- U.S.
- Canada
- Europe (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- South Korea
- Rest of Asia Pacific
- Latin America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Short Bowel Syndrome, By Key Countries, 2025
- 4.2. Pipeline Analysis, By Key Players
- 4.3. New Product Launches, By Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
- 4.5. Regolatory and Reimbursement Scenario, By Key Countries/Region
5. Global GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug
- 5.1.1. Teduglutide
- 5.1.2. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Online & Retail Pharmacies
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug
- 6.1.1. Teduglutide
- 6.1.2. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Online & Retail Pharmacies
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug
- 7.1.1. Teduglutide
- 7.1.2. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Online & Retail Pharmacies
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug
- 8.1.1. Teduglutide
- 8.1.2. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Online & Retail Pharmacies
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug
- 9.1.1. Teduglutide
- 9.1.2. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Online & Retail Pharmacies
- 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug
- 10.1.1. Teduglutide
- 10.1.2. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Online & Retail Pharmacies
- 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Nestle
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Takeda Pharmaceutical Company Limited
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. OxThera
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Zealand Pharma
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Ironwood
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Hanmi Pharm Co., Ltd.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Jaguar Health
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Merck KGaA
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. EnteraBio Ltd.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. Nestle
List of Tables
- Table 1: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 2: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 4: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 5: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 6: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 7: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 8: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 9: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 10: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 11: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 14: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 15: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 16: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 18: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 19: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 22: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 23: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 24: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global GLP-2 Analogs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global GLP-2 Analogs Market Value Share (%), by Drug, 2025 & 2034
- Figure 3: Global GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 5: Global GLP-2 Analogs Market Value Share (%), by Region, 2025 & 2034
- Figure 6: North America GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 7: North America GLP-2 Analogs Market Value Share (%), by Drug, 2025
- Figure 8: North America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 9: North America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
- Figure 10: North America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 11: North America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
- Figure 12: North America GLP-2 Analogs Market Value (USD billion), By Country, 2025 & 2034
- Figure 13: North America GLP-2 Analogs Market Value Share (%), By Country, 2025
- Figure 14: Europe GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 15: Europe GLP-2 Analogs Market Value Share (%), by Drug, 2025
- Figure 16: Europe GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 17: Europe GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
- Figure 18: Europe GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 19: Europe GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
- Figure 20: Europe GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 21: Europe GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 22: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 23: Asia Pacific GLP-2 Analogs Market Value Share (%), by Drug, 2025
- Figure 24: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 25: Asia Pacific GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
- Figure 26: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 27: Asia Pacific GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
- Figure 28: Asia Pacific GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 29: Asia Pacific GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 30: Latin America GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 31: Latin America GLP-2 Analogs Market Value Share (%), by Drug, 2025
- Figure 32: Latin America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 33: Latin America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
- Figure 34: Latin America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 35: Latin America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
- Figure 36: Latin America GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 37: Latin America GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 38: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 39: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Drug, 2025
- Figure 40: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 41: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
- Figure 42: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 43: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
- Figure 44: Middle East & Africa GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 45: Middle East & Africa GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 46: Global GLP-2 Analogs Market Share (%), By Company, 2025
